Oncology Pathways: Consistent Use in Patient Care
- Oncology treatment pathways aim to standardize care, but their consistent use across diverse populations remains under scrutiny.
- Asakura, a lead clinical utilization and intelligence specialist at Kaiser Permanente, discussed the use of treatment pathway tools, designed to guide clinicians toward evidence-based and cost-effective cancer therapies,...
- The study assessed pathway tool utilization using adjusted probability and marginal effects, examining differences across race/ethnicity and insurance types.Disparities were defined as statistically significant differences in adjusted usage...
The consistent use of oncology treatment pathways across diverse patient populations is critical. A new study presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting examines the equitable application of these essential tools, investigating disparities in cancer care, specifically focusing on race, ethnicity, and insurance coverage.Researchers found no preferential treatment among these groups, underscoring the standardized care facilitated through oncology treatment pathways. The research emphasizes the role of pharmacists in promoting optimal patient outcomes through these pathways. Discover how these findings are shaping the future of oncology care, and how healthcare professionals are working to enhance equitable access to the best possible treatments. News Directory 3 keeps you informed on the latest developments in healthcare. Discover what’s next in this crucial area.
Study Examines Equitable Use of Oncology Treatment Pathways
Updated June 03, 2025
Oncology treatment pathways aim to standardize care, but their consistent use across diverse populations remains under scrutiny. At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, laura Momoko Asakura presented research on the equitable application of these tools.
Asakura, a lead clinical utilization and intelligence specialist at Kaiser Permanente, discussed the use of treatment pathway tools, designed to guide clinicians toward evidence-based and cost-effective cancer therapies, across various patient demographics. Her study offers insights into enhancing equity in cancer treatment.
The study assessed pathway tool utilization using adjusted probability and marginal effects, examining differences across race/ethnicity and insurance types.Disparities were defined as statistically significant differences in adjusted usage rates. Asakura noted the absolute differences were small, suggesting minimal clinical impact.
According to Asakura, the pathways were developed to guide physicians toward standardized, evidence-based, and cost-effective treatment options.While equity wasn’t explicitly built into the original design, the analysis examined equal use across patient groups.
The findings suggest that the use of the oncology pathways tool may facilitate equal, standardized cancer care.
Laura Momoko Asakura, PharmD, BCOP, BCSPS, Kaiser Permanente
The analysis focused on race, ethnicity, and insurance, finding no group received preferential treatment. The study did not address geography,language,cancer type,or stage.
Asakura emphasized the role of pharmacists in promoting pathway tool utilization and ensuring patients recieve appropriate, evidence-based medications, regardless of pathway use.
What’s next
Given the study’s findings of equitable pathway tool use, future efforts will focus on encouraging clinicians to continue utilizing these tools to maintain standardized cancer care.